AC
ONCY

AlphaCore Capital’s Oncolytics Biotech ONCY Stock Holding History

AlphaCore Capital’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6K Sell
12,500
-10,000
-44% -$9.95K ﹤0.01% 1111
2025
Q4 		$19.7K Buy
+22,500
New +$24.3K ﹤0.01% 1260

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AlphaCore Capital's ONCY Position: Q1 2026 in Review

AlphaCore Capital reduced its Oncolytics Biotech (ONCY) stake by 44% in Q1 2026, selling an estimated $9.95K and leaving 12,500 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1111.

AlphaCore Capital first reported a position in ONCY in Q4 2025 and has held it in 2 quarters since. The position peaked at $19.7K in Q4 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • AlphaCore Capital held 12,500 shares of Oncolytics Biotech worth $10.6K as of Q1 2026.
  • AlphaCore Capital sold 10,000 Oncolytics Biotech shares in Q1 2026, an estimated $9.95K.
  • Oncolytics Biotech made up ﹤0.01% of AlphaCore Capital's portfolio in Q1 2026, its #1111 holding.
  • AlphaCore Capital first reported a position in Oncolytics Biotech in Q4 2025 and has held it in 2 quarters since.
  • AlphaCore Capital's Oncolytics Biotech position peaked at $19.7K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.